Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study
Aim. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensional (D) ultrasound (US)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2180 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839578245439160320 |
|---|---|
| author | Kl. O. Stumpe E. Agabiti-Rosei T. Zielinski D. Schremmer J. Scholze P. Laeis P. Schwandt M. Ludwig |
| author_facet | Kl. O. Stumpe E. Agabiti-Rosei T. Zielinski D. Schremmer J. Scholze P. Laeis P. Schwandt M. Ludwig |
| author_sort | Kl. O. Stumpe |
| collection | DOAJ |
| description | Aim. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensional (D) ultrasound (US), to compare the effects of a 2-year treatment based on either olmesartan medoxomil or atenolol on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV). Methods. A total of 165 patients (with systolic/diastolic blood pressure 140–180/90–105 mm Hg) were randomized to receive either olmesartan (20–40 mg/day) or atenolol (50–100 mg/day). US was performed at baseline and 28, 52 and 104 weeks. The primary efficacy outcome was the change from baseline (Δ) in CC-IMT assessed by 2D US. Secondary outcomes included ΔPV assessed by 3D US and blood pressure (BP). Results. Olmesartan and atenolol produced comparable significant reductions in CC-IMT; mean ΔIMT (SEM) was −0,090 (0,015) mm for olmesartan and −0,082 (0,014) mm for atenolol. Mean ΔPV was −4,4 (2,3) μl and 0,1 (1,5) μl in the olmesartan and atenolol treated subjects, respectively, without significant between-treatment differences. In the subgroup of patients with baseline PV ≥ median (33,7 μl), significant between-treatment differences existed in ΔPV (p=0,023), because PV regressed significantly with olmesartan (ΔPV: −11,5 (4,4) μl) but not with atenolol (ΔPV: 0,6 (2,5) μl). In these patients BP reductions were comparable. Conclusion. Carotid IMT and BP decreased similarly with olmesartan and atenolol, but only olmesartan reduced the volume of larger atherosclerotic plaques. |
| format | Article |
| id | doaj-art-b4dfa5dc72684c33a2f15daaee8e5e60 |
| institution | Matheson Library |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 1970-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-b4dfa5dc72684c33a2f15daaee8e5e602025-08-04T12:50:08Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-019846541889Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) studyKl. O. Stumpe0E. Agabiti-Rosei1T. Zielinski2D. Schremmer3J. Scholze4P. Laeis5P. Schwandt6M. Ludwig7University of Bonn, Centre of Preventive Medicine, BonnUniversity of Brescia, BresciaKlinika Niewydolnosci Serca i Transplantologii, Instytut Kardiologii, WarszawaGKM Gesellschaft für Therapieforschung mbH, MunichMedizinische Poliklinik, CharitÉ-Universitätsmedizin, BerlinDaiichi Sankyo Europe GmbH, MunichInstitute for Atherosclerosis Prevention, MunichUniversity of Bonn, Benediktus Krankenhaus, TutzingAim. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study was a double-blind trial in patients with hypertension at increased cardiovascular risk with carotid wall thickening and a defined atherosclerotic plaque that used non-invasive 2- and 3-dimensional (D) ultrasound (US), to compare the effects of a 2-year treatment based on either olmesartan medoxomil or atenolol on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV). Methods. A total of 165 patients (with systolic/diastolic blood pressure 140–180/90–105 mm Hg) were randomized to receive either olmesartan (20–40 mg/day) or atenolol (50–100 mg/day). US was performed at baseline and 28, 52 and 104 weeks. The primary efficacy outcome was the change from baseline (Δ) in CC-IMT assessed by 2D US. Secondary outcomes included ΔPV assessed by 3D US and blood pressure (BP). Results. Olmesartan and atenolol produced comparable significant reductions in CC-IMT; mean ΔIMT (SEM) was −0,090 (0,015) mm for olmesartan and −0,082 (0,014) mm for atenolol. Mean ΔPV was −4,4 (2,3) μl and 0,1 (1,5) μl in the olmesartan and atenolol treated subjects, respectively, without significant between-treatment differences. In the subgroup of patients with baseline PV ≥ median (33,7 μl), significant between-treatment differences existed in ΔPV (p=0,023), because PV regressed significantly with olmesartan (ΔPV: −11,5 (4,4) μl) but not with atenolol (ΔPV: 0,6 (2,5) μl). In these patients BP reductions were comparable. Conclusion. Carotid IMT and BP decreased similarly with olmesartan and atenolol, but only olmesartan reduced the volume of larger atherosclerotic plaques.https://cardiovascular.elpub.ru/jour/article/view/2180сarotid arteriesatherosclerosishypertensionolmesartanatenolol |
| spellingShingle | Kl. O. Stumpe E. Agabiti-Rosei T. Zielinski D. Schremmer J. Scholze P. Laeis P. Schwandt M. Ludwig Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study Кардиоваскулярная терапия и профилактика сarotid arteries atherosclerosis hypertension olmesartan atenolol |
| title | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
| title_full | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
| title_fullStr | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
| title_full_unstemmed | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
| title_short | Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study |
| title_sort | carotid intima media thickness and plaque volume changes following 2 year angiotensin ii receptor blockade the multicentre olmesartan atherosclerosis regression evaluation more study |
| topic | сarotid arteries atherosclerosis hypertension olmesartan atenolol |
| url | https://cardiovascular.elpub.ru/jour/article/view/2180 |
| work_keys_str_mv | AT klostumpe carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT eagabitirosei carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT tzielinski carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT dschremmer carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT jscholze carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT plaeis carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT pschwandt carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy AT mludwig carotidintimamediathicknessandplaquevolumechangesfollowing2yearangiotensiniireceptorblockadethemulticentreolmesartanatherosclerosisregressionevaluationmorestudy |